Tortola S, Marcuello E, González I, Reyes G, Arribas R, Aiza G, Sancho F J, Peinado M A, Capella G
Department of Cancer and Metastasis, Institut de Recerca Oncològica, Hospital Duran i Reynals, Barcelona, Spain.
J Clin Oncol. 1999 May;17(5):1375-81. doi: 10.1200/JCO.1999.17.5.1375.
p53 gene and K-ras mutations are among the most common genetic alterations present in colorectal cancer. The prognostic utility of such mutations remains controversial. The purpose of this study was to prospectively evaluate the prognostic significance of p53 and K-ras gene mutations in colorectal cancer.
One hundred forty patients were analyzed. Tumors belonging to the microsatellite mutator phenotype were excluded (n = 8). Mutations at the K-ras and p53 genes were detected and characterized by restriction fragment length polymorphism, single-strand conformation polymorphism, and sequencing, as appropriate.
p53 mutations were detected in 66 (50%) and K-ras mutations were detected in 54 (41%) of the 132 patients. In 26 cases (20%), ras and p53 mutations coexisted; in 38 cases (29%), neither mutation was found. Multivariate analysis of the whole population analyzed (n = 132) showed that survival was strongly correlated with the presence of p53 mutations alone or in combination with K-ras mutations (P = .002; log-rank test). When only patients undergoing a radical resection were considered (R0; n = 101), p53 mutations were no longer of prognostic significance.
p53 mutations alone or in combination with K-ras mutations are correlated with a worse outcome. However, the routine use of these mutations as prognostic markers in the clinical setting is not recommended.
p53基因和K-ras突变是结直肠癌中最常见的基因改变。此类突变的预后价值仍存在争议。本研究的目的是前瞻性评估p53和K-ras基因突变在结直肠癌中的预后意义。
分析了140例患者。排除属于微卫星突变体表型的肿瘤(n = 8)。酌情通过限制性片段长度多态性、单链构象多态性和测序检测并鉴定K-ras和p53基因的突变。
在132例患者中,66例(50%)检测到p53突变,54例(41%)检测到K-ras突变。26例(20%)ras和p53突变共存;38例(29%)未发现任何突变。对全部分析人群(n = 132)进行多变量分析显示,生存与单独存在p53突变或与K-ras突变共同存在密切相关(P = .002;对数秩检验)。仅考虑接受根治性切除的患者(R0;n = 101)时,p53突变不再具有预后意义。
单独的p53突变或与K-ras突变共同存在与较差的预后相关。然而,不建议在临床环境中将这些突变常规用作预后标志物。